L.I. ALEKSEEVA

Nasonova Research Institute of Rheumatology, 34a Kashirskoуe highway, Moscow, Russian Federation, 115522

Alekseeva L.I. — D. Med. Sc., Head of the Department of metabolic diseases of bones and joints with center of osteoporosis prevention, tel. (499) 614-44-61, e-mail: Alekseeva@irramn.ru

This article provides data on treatment of patients with osteoarthrosis. The latest recommendations proposed by The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) are described. These recommendations suggest the sequence of treatment methods for this disease and stress the need to combine the use of drug-free and medical treatment modes.

Key words: osteoarthrosis, recommendations, drug-free and medical treatment modes.

REFERENCES

1. Loeser R.F., Goldring S.R., Scanzello C.R., Goldring M.B. Osteoarthritis – a disease ofthe joint as an organ. Arthritis Rheum., 2012, vol. 64, rr. 1697-707.
2. Conaghan P.G. Osteoarthritis in 2012: parallel evolution of OA phenotypes andtherapies. Nat Rev Rheumatol., 2013, vol. 9, rr. 68-70.
3. Jordan K.M., Arden N.K., Doherty M. et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis., 2003, vol. 62, rr. 1145-55.
4. Zhang W., Doherty M., Arden N. et al. EULAR evidence based recommendationsfor the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis., 2005, vol. 64, rr. 669-81.
5. Zhang W., Doherty M., Leeb B.F. et al. EULAR evidence based recommendationsfor the management of hand osteoarthritis: report of a Task Force of the EULARStanding Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis., 2007, vol. 66, rr. 377-88.
6. Zhang W., Moskowitz R.W., Nuki G. et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage, 2007, vol. 15, rr. 981-1000.
7. Zhang W., Moskowitz R.W., Nuki G. et al. OARSI recommendations for the management of hip and knee osteoarthritis, part II. – OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage, 2008, vol. 16, rr. 137-62.
8. Zhang W., Nuki G., Moskowitz R.W. et al. OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence followingsystematic cumulative update of research published through January 2009. Osteoarthritis Cartilage, 2010, vol. 18, rr. 476-99.
9. McAlindon T.E., Bannuru R.R., Sullivan M.C., Arden N.K., Berenbaum F., Bierma-Zeinstra S.M. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage, 2014, vol. 22, rr. 363-88.
10. Reginster J.Y., Deroisy R., Rovati L.C. et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet, 2001, vol. 357, rr. 251-6.
11. Pavelka K., Gatterova J., Olejarova M. et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med., 2002, vol. 162, rr. 2113-23.
12. Michel B.A., Stucki G., Frey D. et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum., 2005, vol. 52, rr. 779-86.
13. Kahan A., Uebelhart D., De Vathaire F. et al. Long-term effects of chondroitins 4and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progressionprevention, a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum., 2009, vol. 60, rr. 524-33.
14. Clegg D.O., Reda D.J., Harris C.L., Klein M.A., O’Dell J.R., Hooper M.M. et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med., 2006, vol. 354, rr. 795-808.
15. Hochbergy M.C. et al. The Multicentric Osteoarthritis inter VEntion Study with Sysadoa (MOVES). MOVES Steering Committee. Osteoarthritis and Cartilage, 22 (2014), rr7-S56.
16. Martel-Pelletier1 J., Roubille1 C., Abram F., M.C. Hochberg et al. Data from the osteoarthritis initiative progression cohort Published Online First 13 December 2013.
17. Fransen M., Agaliotis M., Nairn L. et al. Glucosamine and chondroitin for knee placebo– controlled clinical trial evaluating osteoarthritis: a double-blind randomised single and combination regimens. Ann Rheum Dis. – 2014;0:1–8doi. – 10.1136/annrheumdis-2013-203954.
18. Bruyère O., Cooper C., Pelletier J.-P., Branko J., Brandy M.L. et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally. – A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) / Seminars in Arthritis and Rheumatism, 2014. Rr. 2-11.
19. Fernandes L., Hagen K.B., Bijlsma J.W., Andreassen O., Christensen P., Conaghan P.G. et al. EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis. Ann Rheum Dis., 2013, vol. 72, rr. 1125-35.
20. Bjordal J.M., Klovning A., Ljunggren A.E., Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a metaanalysis of randomised placebo-controlled trials. Eur J Pain, 2007, vol. 11, rr. 125-38.
21. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Bhala N, Emberson J, Merhi A, Abramson S, Arber N. et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet, 2013, vol. 382, rr. 769-79.
22. Bannuru R.R., Natov N.S., Dasi U.R., Schmid C.H., McAlindon T.E. Therapeutic trajectory following intra-articular hyaluronic acid injection in knee osteoarthritis – meta-analysis. Osteoarthritis Cartilage, 2011, vol. 19, rr. 611-9.
23. Bannuru R.R., Vaysbrot E.E., Sullivan M.C., McAlindon T.E. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum., 2013, vol. 43, rr. 593-9 [pii. S0049-0172(13)00206-0].
24. Bannuru R.R., Natov N.S., Obadan I.E., Price L.L., Schmid C.H., McAlindon T.E. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum., 2009, vol. 61, pp. 1704-11.
25. Risser R.C., Hochberg M.C., Gaynor P.J., D’Souza D.N., Frakes E.P. Responsiveness of the Intermittent and Constant Osteoarthritis Pain (ICOAP) scale in a trial of duloxetine for treatment of osteoarthritis knee pain. Osteoarthritis Cartilage, 2013, vol. 21, rr. 691-4.